Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 11/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 11/20 | 0.61 |
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727624 | 0.86 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL19322155 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL4728028 | 0.83 | MAPT (0.82) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| Zolimidine SCHEMBL932657 | 0.82 | HDAC6 (1.00) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL12799208 | 0.81 | RAB9A (0.65) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL30366944 | 0.81 | RAB9A (0.69) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| Zolimidine SCHEMBL29405502 | 0.81 | HDAC6 (0.97) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL13325909 | 0.81 | RAB9A (0.83) | KDM4EALDH1A1POLBMAPTMAPK1 | |
| SCHEMBL10754624 | 0.79 | KMT2A (1.00) | KDM4EALDH1A1POLBMAPTHPGD | |
| SCHEMBL13325938 | 0.79 | RAB9A (0.80) | KDM4EALDH1A1POLBMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008029152-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2008-03-13 | — | — | WO | disclosed |
| US-6916826-B2 | Substituted imidazo[1,2-a]pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6861437-B2 | Substituted imidazo [1,2-a] pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1381363-B1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-12-08 | — | — | EP | disclosed |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | MUTEL VINCENT (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1381363-A1 | IMIDAZO [1,2-A]-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-21 | — | — | EP | disclosed |
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | MUTEL VINCENT (FR) | 2003-11-13 | — | — | US | disclosed |
| US-6596731-B2 | An imidazo(1,2-a)pyridine derivative useful for treating chronical or acute neurological disorders, cognitive disorders and memory deficits | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-12 | — | — | US | disclosed |
| WO-2002092086-A1 | IMIDAZO (1,2-A)-PYRIDINE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212096-A1 | Substituted imidazo [1,2-a] pyridine derivatives | GRM5, GRM1, GRIK5 | KDM4E 2868/4885ALDH1A1 1154/4885POLB 4703/4885 |
| US-20040180921-A1 | Substituted imidazo[1,2-a]pyridine derivatives | GRM5, GRM1, GRIK5 | KDM4E 2868/4885ALDH1A1 1154/4885POLB 4703/4885 |
| US-20020188128-A1 | Substituted imidazo[1,2-A] pyridine derivatives | GRM5, GRM1, GRIK5 | KDM4E 2868/4885ALDH1A1 1154/4885POLB 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.